GlassScriptPhysician profile
Nitya S Chandra
NPI 1013197995
$4,333.30
in general payments reported to CMS, 2019-2025
25 companies · $422 in 2025
The $422 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.29 · 2020: $182 · 2021: $527 · 2022: $788 · 2023: $789 · 2024: $1,595 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $842.92 | 2024-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $445.95 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.82 | 2020-2025 | Jardiance |
| Pfizer INC. | $291.92 | 2020-2025 | |
| Impulse Dynamics (USA) INC. | $249.27 | 2022-2024 | Optimizer, Optimizer |
| Alnylam Pharmaceuticals INC. | $214.67 | 2021-2025 | Amvuttra, Onpattro |
| Novo Nordisk INC | $200.04 | 2021-2023 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $199.28 | 2022-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $188.94 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $184.85 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $183.06 | 2020-2025 | Farxiga |
| Daiichi Sankyo INC. | $159.67 | 2021-2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $155.97 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $155.78 | 2021-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $107.53 | 2020-2024 | Opsumit, Uptravi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $107.32 | 2022-2024 | Impella |
| Boston Scientific Corporation | $79.57 | 2021-2024 | Watchman Flx, Watchman Access System |
| Amgen INC. | $50.85 | 2022-2023 | Repatha |
| United Therapeutics Corporation | $39.66 | 2021-2022 | |
| Atricure, INC. | $38.87 | 2023 | |
| Abbott Laboratories | $36.90 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.41 | 2021 | |
| Scpharmaceuticals INC. | $28.80 | 2023-2025 | |
| Heartflow, INC. | $21.45 | 2025 | |
| Kestra Medical Technology Services, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitya Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.